Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 10/20 | 0.61 |
| ▸ | THRB | P10828 | 10/20 | 0.61 |
| ▸ | RARB | P10826 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | RARA | P10276 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.56 |
| ▸ | ATG4B | Q9Y4P1 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13246796 | 1.00 | THRA (0.61) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL13246795 | 1.00 | THRA (0.61) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL11664614 | 0.98 | RARB (0.60) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL10001142 | 0.93 | RARB (0.59) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL10712859 | 0.88 | THRA (0.59) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL10713905 | 0.88 | THRA (0.59) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL195074 | 0.88 | THRA (0.59) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL151548 | 0.88 | THRA (0.59) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL6692949 | 0.88 | THRA (0.59) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL6702544 | 0.88 | THRA (0.59) | THRATHRBRARBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8507647-B2 | Antibacterial agents for the treatment of gram positive infections | CUBIST PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | THRA 4272/4885THRB 4542/4885RARB 4537/4885 |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | THRA 4272/4885THRB 4542/4885RARB 4537/4885 |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | THRA 4272/4885THRB 4542/4885RARB 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.